- Home
- TGB vs EYPT Comparison
TGB vs EYPT Comparison
Compare TGB & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGB | EYPT |
|---|---|---|
| Founded | 1966 | 1987 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Laboratory Analytical Instruments |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | TGB | EYPT |
|---|---|---|
| Price | $5.18 | $16.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $29.60 |
| AVG Volume (30 Days) | ★ 6.2M | 1.1M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $428,559,326.00 | $42,339,000.00 |
| Revenue This Year | $10.35 | N/A |
| Revenue Next Year | $61.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.50 | N/A |
| 52 Week Low | $1.67 | $3.91 |
| 52 Week High | $5.57 | $19.11 |
Technical Indicators
Market Signals| Indicator | TGB | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 62.09 |
| Support Level | $5.03 | $15.81 |
| Resistance Level | $5.57 | $17.40 |
| Average True Range (ATR) | 0.23 | 0.98 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 29.46 | 56.18 |
Price Performance
Historical ComparisonAbout TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.